Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15277MR)

This product GTTS-WQ15277MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioma Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15277MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11721MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ6780MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ7569MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ5845MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ6054MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ1067MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ15081MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ99MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 1121B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW